Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Lymphoma 3Solid Tumors 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Sarcoma 1Recurrence 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Leukemia 1Hematologic Neoplasms 1Carcinoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 15fludarabine phosphate 12Filgrastim 10Peripheral Blood Stem Cell Transplantation 9ruxolitinib 8Decitabine 8fludarabine 7Tacrolimus 7Etoposide 7Melphalan 6Cytarabine 6Azacitidine 6Vorinostat 5Mycophenolic Acid 5Ipilimumab 5venetoclax 4Specimen Handling 4Sirolimus 4Idarubicin 4Granulocyte Colony-Stimulating Factor 4ivosidenib 3fedratinib 3aldesleukin 3Whole-Body Irradiation 3Rituximab 3Radiotherapy 3Nivolumab 3Methylprednisolone 3Imatinib Mesylate 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Myeloproliferative Disorders × darinaparsin × Clear all
NCT00592046 2012-07-19

A Phase I Trial of ZIO-101 in Hematologic Cancers

Alaunos Therapeutics

Phase 1 Completed
12 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡